Rahul Dhanda

Form D signer

Rahul Dhanda

Chief Executive Officer at Syntis BIO

Form D signer

Capital raised by Syntis BIO

$31.3M+$25.0M latest round

2 Form D filings · first filed Dec 2024 · Boston, MA

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 2
FOUNDED: 2022
30D INTEREST: 1 ↗

Career

1 company on file · founded 2022

Syntis BIOBiotech · Boston, MAsince 2022

Chief Executive Officer

Signatory on Syntis BIO's Form D filings · $31.3M raised across 2

Company filings

via EDGAR · Form D for Syntis BIO2

DateCompanyFormAmountRole on filing

Jun 17, 2025Syntis BIOForm D+$25.0MChief Executive Officer

Form DJun 17, 2025 · Syntis BIO+$25.0Mas Chief Executive Officer

Dec 30, 2024Syntis BIOForm D+$6.3MChief Executive Officer

Form DDec 30, 2024 · Syntis BIO+$6.3Mas Chief Executive Officer

Overview

Last filing Jun 17, 2025

Rahul Dhanda is on file as Chief Executive Officer at Syntis BIO in Boston, MA. Syntis BIO has 2 Form D filings on record, $31.3M raised in total. Rahul Dhanda appears as a signatory on the company's filings.

Teammates

Syntis BIO · 1

Michael NannizziDirector

Products

Syntis BIO · 1

SYNT-101Oral Therapeutic Platform

SYNT-101 is an innovative oral pill designed to adjust the small intestine's role in metabolism, mimicking the effects of gastric bypass surgery to aid in weight loss management.